KRAS mutation analysis on low percentage of colon cancer cells: The importance of quality assurance

Virchows Archiv

Volumn 462, Issue 1, 2013, Pages 39-46

  Dijkstra, J R ^a   Heideman, D A M ^b   Meijer, G A ^b   Boers, J E ^c   'T Hart, N A ^c   Diebold, J ^d   Hirschmann, A ^d   Hoefler, G ^e   Winter, G ^e   Miltenberger Miltenyi, G ^f   Pereira, S V ^f   Richman, S D ^g   Quirke, P ^g   Rouleau, E L ^h   Guinebretiere, J M ^h   Tejpar, S ⁱ   Biesmans, B ⁱ   Van Krieken, J H J M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c Isala Klinieken ^*  (Netherlands)

^d Pathologische Institut am Kantonsspital Luzern   (Switzerland)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h INSTITUT CURIE   (France)

ⁱ UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Colon cancer; EQA; KRAS; Mutation

Indexed keywords

K RAS PROTEIN;

ARTICLE; CANCER CELL; COLON CANCER; DNA EXTRACTION; GENE AMPLIFICATION; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; QUALITY CONTROL; SENSITIVITY ANALYSIS;

ADENOCARCINOMA; CELL COUNT; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENES, RAS; HUMANS; LIMIT OF DETECTION; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; QUALITY ASSURANCE, HEALTH CARE; RAS PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84872301767     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1356-2     Document Type: Article

References (22)

1. Lockhart AC, Berlin JD (2005) The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32:52-60
2. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174
3. Amado RG, Wolf M, Peeters M, van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634
4. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
5. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379
6. European Medicines Agency (2008) Committee for Medicinal Product for Human Use, May 2008 plenary meeting monthly report. London
7. rd, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, Fuchs C, Grem JL, Kiel L, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C, National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 7:778-831
8. Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, Edsjo A, Gorgoulis V, Hofler G, Jung A, Kotsinas A, Laurent-Puig P, Lopez-Rios F, Hansen TP, Rouleau E, Vandenberghe P, van Krieken JJ, Dequeker E (2011) External quality assessment for KRAS testing is needed: setup of a european program and report of the first joined regional quality assessment rounds. Oncologist 16:467-478
9. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Flejou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417-431
10. Querings S, Altmuller J, Ansen S, Zander T, Seidel D, Gabler F, Peifer M, Markert E, Stemshorn K, Timmermann B, Saal B, Klose S, Ernestus K, Scheffler M, Engel-Riedel W, Stoelben E, Brambilla E, Wolf J, Nurnberg P, Thomas RK (2011) Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One 6:e19601
11. Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, Murphy KM (2010) Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn 12:425-432
12. Angulo B, Garcia-Garcia E, Martinez R, Suarez-Gauthier A, Conde E, Hidalgo M, Lopez-Rios F (2010) A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn 12:292-299
13. Feigelson HS, Goddard KA, Johnson MA, Funk KC, Rahm AK, Kauffman TL, Chitale DA, Le Marchand L, Richards CS (2012) Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. BMC Res Notes 5:196
14. Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, Gyuris T, Baron W, Bakker A, Parker A, Patterson SD (2010) A comparability study of 5 commercial KRAS tests. Diagn Pathol 5:23
15. Weichert W, Schewe C, Lehmann A, Sers C, Denkert C, Budczies J, Stenzinger A, Joos H, Landt O, Heiser V, Rocken C, Dietel M (2010) KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology. J Mol Diagn 12:35-42
16. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox S, Scott RJ, Dobrovic A, Iacopetta B (2009) A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 11:543-552
17. Dijkstra JR, Opdam FJ, Boonyaratanakornkit J, Schonbrunner ER, Shahbazian M, Edsjo A, Hoefler G, Jung A, Kotsinas A, Gorgoulis VG, Lopez-Rios F, de Stricker K, Rouleau E, Biesmans B, van Krieken JH (2012) Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis. J Mol Diagn 14:187-191
18. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931-5937
19. Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, Doan S, Barkoh BA, Koeppen H, Medeiros LJ, Luthra R (2009) Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 22:1023-1031
20. Dijkstra JR, Mekenkamp LJ, Teerenstra S, De Krijger I, Nagtegaal ID (2011) MicroRNA expression in formalin-fixed paraffin embedded tissue using real time quantitative PCR; the strengths and pitfalls. J Cell Mol Med 16:683-90
21. Kramer D, Thunnissen FB, Gallegos-Ruiz MI, Smit EF, Postmus PE, Meijer CJ, Snijders PJ, Heideman DA (2009) A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutations. Cell Oncol 31:161-167
22. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P (2001) Unlocking the archive - gene expression in paraffin-embedded tissue. J Pathol 195:66-71